Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD8 alpha

CD8 alpha

Brief Information

Name:Cluster of differentiation 8
Target Synonym:CD8 Antigens
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CDA-C82E7-ELISA
 CD8 alpha ELISA

Immobilized Biotinylated Cynomolgus CD8 alpha Protein, His,Avitag (Cat. No. CDA-C82E7) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD8 alpha Antibody, Human IgG1 with a linear range of 0.06-1 ng/mL (QC tested).

CDA-C82E7-MALS-HPLC
CD8 alpha MALS images

The purity of Biotinylated Cynomolgus CD8 alpha Protein, His,Avitag (Cat. No. CDA-C82E7) is more than 90% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.

Synonym Name

CD8A,CD8,Leu2,MAL,p32

Background

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GRANITE GRANITE-001; GRT-C901/GRT-R902 Phase 3 Clinical Bristol-Myers Squibb Company, Gritstone Bio Inc Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
89Zr-Df-crefmirlimab IAB-22-M2C Phase 3 Clinical Imaginab Inc Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Multiple Sclerosis; Lymphoma; Leukoencephalopathy, Progressive Multifocal; Melanoma; Carcinoma, Non-Small-Cell Lung Details
RB-0003 RB-0003; BNT-111 Phase 2 Clinical Biontech Se, Tron Melanoma Details
GEN-009 GEN-009 Phase 2 Clinical Genocea Biosciences Inc Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
VE-800 VE-800 Phase 2 Clinical Vedanta Biosciences Inc Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Melanoma; Neoplasm Metastasis Details
EBViNT Cell (Eutilex) Phase 2 Clinical Eutilex Lymphoma, Extranodal NK-T-Cell Details
ZED88082A ZED88082A Phase 2 Clinical Umcg The University Medical Center Groningen Neoplasms; Neoplasm Metastasis Details
NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center, National Cancer Institute Liposarcoma; Sarcoma, Synovial; Sarcoma Details
Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital School Of Zhejiang University School Of Medicine Esophageal Neoplasms; Stomach Neoplasms Details
SCRI-E2CAR_EGFRtv1 SCRI-E2CAR_EGFRtv1 Phase 1 Clinical Umoja BioPharma Inc Osteosarcoma Details
68-Ga-NODAGA-SNA-006 SNA-006; 68-Ga-NODAGA-SNA-006 Phase 1 Clinical Smartnuclide Biopharma Solid tumours Details
GRANITE GRANITE-001; GRT-C901/GRT-R902 Phase 3 Clinical Bristol-Myers Squibb Company, Gritstone Bio Inc Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
89Zr-Df-crefmirlimab IAB-22-M2C Phase 3 Clinical Imaginab Inc Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Multiple Sclerosis; Lymphoma; Leukoencephalopathy, Progressive Multifocal; Melanoma; Carcinoma, Non-Small-Cell Lung Details
RB-0003 RB-0003; BNT-111 Phase 2 Clinical Biontech Se, Tron Melanoma Details
GEN-009 GEN-009 Phase 2 Clinical Genocea Biosciences Inc Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
VE-800 VE-800 Phase 2 Clinical Vedanta Biosciences Inc Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Melanoma; Neoplasm Metastasis Details
EBViNT Cell (Eutilex) Phase 2 Clinical Eutilex Lymphoma, Extranodal NK-T-Cell Details
ZED88082A ZED88082A Phase 2 Clinical Umcg The University Medical Center Groningen Neoplasms; Neoplasm Metastasis Details
NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center, National Cancer Institute Liposarcoma; Sarcoma, Synovial; Sarcoma Details
Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital School Of Zhejiang University School Of Medicine Esophageal Neoplasms; Stomach Neoplasms Details
SCRI-E2CAR_EGFRtv1 SCRI-E2CAR_EGFRtv1 Phase 1 Clinical Umoja BioPharma Inc Osteosarcoma Details
68-Ga-NODAGA-SNA-006 SNA-006; 68-Ga-NODAGA-SNA-006 Phase 1 Clinical Smartnuclide Biopharma Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message